LINC 2023: Late-breaking Science Video Collection
Published: 20 June 2023
-
Views:
1035
-
Likes:
7
-
Views:
1035
-
Likes:
7
-
5m 2sPart 1 | Session 1 AVPAS: Lutonix AV Post-Approval Study Scott O Trerotola
-
5m 18sPart 1 | Session 2 The ELEGANCE Registry: Ranger DCB In Under-Represented Groups Marianne Brodmann
-
4m 51sPart 1 | Session 3 RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety Marianne Brodmann
-
4m 48sPart 1 | Session 4 IN.PACT AV ACCESS: Outcomes to Date Matteo Tozzi
-
8m 14sPart 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes Koen Deloose
-
7m 13sPart 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease Yoshimitsu Soga
-
3m 49sPart 1 | Session 7 MOTIV Bioresorbable Scaffold in BTK Lesions Michel Bosiers
-
6m 6sPart 1 | Session 8 Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK Marc Sirvent
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
Expert Interviews
Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
About the episode
LINC 23 - We are joined by Principal Investigator, Dr Sahil Parikh (Columbia University Irving Medical Center, US) to discuss Abbott's LIFE-BTK Randomised Controlled Trial.
The primary objective of the LIFE-BTK study was to assess the safety and effectiveness of the Esprit BTK everolimus-eluting system in treating narrowed infrapopliteal lesions in patients with critical limb ischemia. The full study design was released at LINC 23, where patients with peripheral artery disease specifically with below-the-knee arterial narrowing were randomized 2:1 to receive either treatment with the Esprit bioresorbable scaffold or balloon angioplasty.
Interview Questions:
- What is the importance of this trial?
- Please describe the Esprit BTK device and its unique features.
- What were the study design and patient population?
- What was the key focus of the trial?
- What are the next steps?
Recorded remotely from New York, 2023.
Editor: Jordan Rance
Video Specialist: Dan Brent
Faculty Biographies

Sahil Parikh
Director of Endovascular Services and Assistant Professor of Medicine
Dr Sahil Parikh is Director of Endovascular Services and Assistant Professor of Medicine at Columbia University Vagelos College of Physicians & Surgeons in New York. His research interests include coronary artery disease, peripheral arterial disease including claudication, critical limb ischemia, renovascular disease, cerebrovascular disease, venous medicine and thrombosis.
Dr Parikh has authored over 50 original manuscripts and reviews, and frequently lectures at national meetings, including TCT, ACC and SCAI.
Comments